Ildiko T.

Research spans major solid cancers such as Non‑Small Cell Lung Cancer and gastrointestinal malignancies.

• Therapies for Advanced Non‑Small Cell Lung Cancer
• Targeted treatment of Cholangiocarcinoma
• Clinical development in Pancreatic Ductal Adenocarcinoma
• Management of Metastatic Colorectal Cancer
• Approaches for Head and Neck Squamous Cell Carcinoma

Focus is placed on improving survival across diverse solid tumor entities.

Investigator evaluates agents directed at specific genetic alterations, such as KRAS p.G12C and EGFR exon 20 insertions.

• Exploration of KRAS‑mutated tumor inhibitors
• Study of HER2‑mutated lung cancer agents
• Investigation of BRCA‑mutated breast cancer therapies
• Evaluation of NRG1‑fusion directed compounds
• Research on ESR1‑mutated endocrine resistance

These efforts aim to translate molecular insights into precise therapeutic options.

Investigator is active in the development of immune‑based treatments, including CAR‑T cell and bispecific antibodies.

• Clinical evaluation of CAR‑T cell products for lymphoma
• Assessment of bispecific T‑cell engagers in B‑cell malignancies
• Investigation of immune checkpoint inhibitors across tumor types
• Studies on gene‑modified T‑cell persistence and safety
• Combination strategies involving immunomodulatory drugs

Goal is to enhance anti‑tumor immunity through innovative biologic platforms.

Investigator’s work includes hormone‑responsive and HER2‑related breast cancer, such as HR‑positive/HER2‑negative disease.

• Therapies for Estrogen Receptor‑positive breast cancer
• Studies on HER2‑low breast cancer with brain metastases
• Investigation of CDK4/6 inhibitors in adjuvant settings
• Evaluation of PARP inhibitors in BRCA‑mutated patients
• Research on triple‑negative breast cancer immunotherapy

Efforts target improving disease‑free and overall survival for diverse breast cancer subtypes.